The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.
Improvements in positive symptoms of schizophrenia include hallucinations and delusions.
Improvements in negative symptoms of schizophrenia include affective flattening, alogia, anhedonia, motivation, and asociality.
Improvements in cognitive dysfunction include attention/vigilance, reasoning, problem-solving, processing speed, working memory, verbal learning and memory, visual learning and memory, and social cognition.
Extrapyramidal side effects (EPS) include dystonia, Parkinsonism, akathisia, and tardive dyskinesia.
Side effects related to postsynaptic dopamine receptor blockade include EPS, prolactin elevation, and sexual side effects.
Anticholinergic side effects include constipation and dyspepsia.
Cardiometabolic side effects include weight gain, dyslipidemia, and hyperglycemia.1
Read more about Novel and Emerging Pharmacologic Treatments for Schizophrenia
Related content
Professors Shen-Yang Lim and Christoph Correll explore dopamine’s role in Parkinson’s disease and schizophrenia, discussing treatment evolution, side effects, and parallels between the disorders. Access more resources at Neurotorium.org.
Professors Christoph Correll and Gabriele Fischer discuss the challenges of managing co-occurring schizophrenia and substance use disorders, offering insights into this complex comorbidity.
The use of virtual reality in the treatment of severe mental illnesses